Palvella Received $5 Million Upfront Payment QTORIN„¢ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients...
QTORIN„¢ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations Microcystic Lymphatic Malformations is a chronically...
MINNEAPOLIS, July 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the presentation...
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies
Palvella Therapeutics Announces Pipeline Update on QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases...
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
Palvella Therapeutics, Inc., a rare-disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious, rare genodermatoses with no approved treatments, announced that the Phase 3 pivotal portion of the seamless Phase 2/3 VALO Study of PTX-022 (QTORIN™ 3.9% rapamycin anhydrous gel) for the treatment of patients with pachyonychia congenita (PC) has commenced.
MedPharm and Palvella expand pachyonychia congenita partnership
MedPharm announced the expansion of their partnership with Palvella Therapeutics. To date, MedPharm has employed its specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). MedPharm has also made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.